Coordinating Implementation Science for CAB for PrEP: Focus on Delivery Models
This second meeting of the BioPIC implementation science series focused on how cabotegravir (CAB) for PrEP can be integrated into existing community, pharmacy and facility-based delivery for HIV prevention.
RISE CAB-LA Training Toolkit
With the release of the WHO Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention in 2022, HIV prevention programs and implementing partners are working to prepare for rapid expansion of additional methods of HIV pre-exposure prophylaxis (PrEP). Experience from the scale-up of previous HIV prevention programs demonstrates the advantages of ready-made provider capacity building resources…
Optimizing Uptake of Long-Acting Injectable Pre-exposure Prophylaxis for HIV Prevention for Men Who Have Sex with Men
This article from AIDS and Behavior describes the results of a discrete choice experiment on preferences for oral or injectable PrEP amongst gay, bisexual, and other men who have sex with men in the USA, including mode of administration, side-effects, monetary cost, and time cost.
HIV Prevention User Journey Tool
The HIV Prevention Journey Tool was developed to support adolescent girls and young women to explore methods that would align with their lifestyle, needs and personal preferences; and support healthcare providers to provide informed counseling based on client needs. The digital tool, which has been optimized for use on mobile devices, can be accessed here.…
An Update on Expanding HIV Preexposure Prophylaxis
This article from the Journal of the American Academy of Physicians Assistants describes how to better employ PrEP in the United States in light of changes to the Centers for Disease Control guidelines on PrEP counselling, monitoring, and delivery, and approval of injectable cabotegravir for PrEP by the US Food and Drug Administration.
Estimating the Impact of HIV PrEP Regimens Containing Long-acting Injectable Cabotegravir or Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine among Men who Have Sex with Men in the United States: A mathematical modelling study for HPTN 083
This article from The Lancet Regional Health- Americas describes the results of a modelling exercise which compares the potential population-level impact of oral PrEP (TDF/FTC) and Cabotegravir for PrEP among gay and bisexual men who have sex with men in Atlanta, Georgia, USA.
The Potential of Long-Acting, Injectable PrEP, and Impediments to its Uptake
This article from the Journal of Urban Health outlines potential advantages and barriers to uptake of cabotegravir for PrEP.
Predicted Effects of the Introduction of Long-acting Injectable Cabotegravir Pre-exposure Prophylaxis in Sub-Saharan Africa: A modelling study
This article from The Lancet HIV uses modelling to project the health benefits and risks of cabotegravir for PrEP introduction in settings in sub-Saharan Africa.
Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A systematic literature review
This article from PharmacoEconomics synthesizes findings on cost and cost-effectivness of different biomedical HIV prevention options and identifies remaining knowledge gaps to suggest future research priorities.
Long-acting HIV Pre-exposure Prophylaxis (PrEP) Approaches: Recent advances, emerging technologies, and development challenges
This review from Expert Opinion on Drug Delivery discusses the current state of the long acting PrEP field, recent advances, and emerging technologies, including ARV prodrug modifications and new drug delivery systems. Technological challenges, knowledge gaps, preclinical testing considerations, and future directions important in the context of clinical translation and implementation of long acting HIV…
HIV Prevention for the Next Decade: Appropriate, person-centred, prioritised, effective, combination prevention
In light of the development of new HIV prevention technologies, this article from PLOS Medicine proposes a new approach to HIV prevention, that emphasises appropriate, person-centred, prioritised, effective, combination HIV prevention within a framework that reduces existing barriers to services and acknowledges heterogeneity, autonomy, and choice.